The financial experts who work for StockNews.com have shifted their recommendation for ProQR Therapeutics (NASDAQ: PRQR), moving it from a “hold” rating to a “sell” rating, as stated in a report that was published on Thursday.
Recent events have resulted in PRQR receiving feedback from a wide range of different equity research analysts. In a research note published on Friday, December 23, Raymond James increased their price target for ProQR Therapeutics from two dollars to five dollars, giving the company an “outperform” rating. Raymond James also gave the company an “outperform” rating in their published report. Cantor Fitzgerald upgraded its rating on ProQR Therapeutics from “neutral” to “overweight” and increased its price target for the stock to $5.00 in a research report published on Thursday, December 22. One research analyst suggested purchasing additional shares, three suggested maintaining the current holdings, four suggested maintaining the current holdings, and four suggested purchasing additional shares. The information that can be found on Bloomberg.com reveals that the typical recommendation for ProQR Therapeutics is “hold,” and the data also reveals that the typical price objective for the company is $3.75. In addition, the website’s information reveals that the average price target for the company is $3.75.
At the market’s opening on Thursday, the price of NASDAQ: PRQR was $3.18. The price of ProQR Therapeutics has been as low as $0.53 and as high as $6.50 during its 52-week trading range. It can be seen that the debt-to-equity ratio, the current ratio, and the quick ratio are all equal to 3.86. The ratio of debt to equity is 0.07 right now. The firm’s beta value is 0.19, and its market capitalization currently stands at $226.71 million. At a value of 2.94, the price-to-earnings ratio is negative. According to the simple moving average calculated over the past 200 days, the stock price is currently $1.28, while the simple moving average calculated over the past 50 days puts it at $2.13.
On November 9, the most recent quarterly earnings report for ProQR Therapeutics, traded on the NASDAQ under the PRQR, was made public. The reported earnings per share for the quarter was $0.34, which was $0.11 lower than the consensus estimate of $0.23. reported earnings per share for the quarter of $0.34, which was $0.11 lower than the consensus estimate of $0.23. reported earnings per share for the quarter of $0.34, which was $0.11 lower than the consensus estimate of $0.23. ProQR Therapeutics had a negative return on equity of 76.32 percent, and the company’s net margin was negative to the tune of 2,075.42 percent. The company’s quarterly sales came in at $0.96 million, which is significantly lower than the consensus projection of $1.05 million for the quarter’s sales. According to the estimates provided by sell-side analysts, the current fiscal year of ProQR Therapeutics is expected to result in a loss of 0.97 cents per share, which places the company’s earnings in the red.
There has been a recent shift in the percentage of PRQR shares held by certain institutional investors. This shift has been brought about by recent market activity. JPMorgan Chase & Co. increased the amount of ProQR Therapeutics stock owned by 37.8 percent during the first three months of 2018. JPMorgan Chase & Co. has increased its interest in the biopharmaceutical company by purchasing an additional 268,315 shares of the company’s stock. This brings the total number of shares it owns in the company to 977,794, valued at $885,000 to 977,794.JPMorgan Chase & Co. has also increased its investment in the company. BlackRock Inc. increased its holdings in ProQR Therapeutics by 8.1% during the first three months of 2018. After making an additional purchase of 39,482 shares during the most recent quarter, BlackRock Inc. now has 527,396 shares in the biopharmaceutical business. These shares are currently valued at $477,000, and the company owns these shares. A new investment in ProQR Therapeutics shares with a value of approximately 191,000 dollars was made by XTX Topco Ltd. during the first three months of 2018. Renaissance Technologies LLC opened a new position in ProQR Therapeutics shares during the first three months of 2018, with a total value of approximately $547,000. And finally, during the second quarter of the fiscal year, Franklin Street Advisors Inc. increased the proportion of its holdings invested in ProQR Therapeutics by 50.0%. Because of the purchase of an additional 50,000 shares during the most recent quarter, Franklin Street Advisors Inc. (NC) now has a total of 150,000 shares of the biopharmaceutical company’s stock, which has a value of $117,000; this brings the company’s overall holdings to a value of $117,000. Shares of the company are owned by hedge funds and other types of institutional investors to a combined total of 29.79%.
At this early stage in its development, the biopharmaceutical company that goes by the name ProQR Therapeutics NV is still in the infant stages. Its primary objective is to discover and develop RNA treatments for the treatment of severe genetic rare diseases, with a particular emphasis on inherited retinal diseases such as Leber congenital amaurosis 10 (LCA10), Usher syndrome type 2 (USH), and autosomal dominant retinitis pigmentosa (ADRP) (RP). This objective is being pursued with a particular emphasis on inherited conditions affecting the retina.
